Siramesine H Lundbeck
by
Heading C.
moore11@globalnet.co.uk
Curr Opin Investig Drugs. 2001 Feb;2(2):266-70

ABSTRACT

Siramesine is a sigma2 opioid agonist under development by H Lundbeck as a potential treatment for anxiety 11678721. In March 1998, the compound was licensed to Forest Laboratories under a strategic alliance [282593]. In August 2000, siramesine entered phase II trials [378814]. Phase III trials are expected to take place in 2002 [387270]. A series of compounds have been synthesized by Lundbeck, the most potent of which may serve as a backup compound [179036].

Antidepressants
Enkephalinase inhibitors
Sigma agonists and pain
Igmesine: sigma ligand and antidepressant
Sigma-receptor ligands and anti-stress actions

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family